Equity Incentive Plans (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		6 Months Ended		12 Months Ended
	Jan. 20, 2017	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Jun. 16, 2022
Options
Outstanding balance at the beginning of the period (in shares)				8,525,618
Granted (in shares)				745,000
Forfeited (in shares)				(224,198)
Outstanding balance at the end of the period (in shares)		9,046,420		9,046,420		8,525,618
Options exercisable at the end of the period (in shares)		6,499,613		6,499,613
Options vested and expected to vest at end of period (in shares)		9,046,420		9,046,420
Weighted Average Exercise Price Per Share
Outstanding balance at the beginning of the period (in dollars per share)				$ 4.48
Granted (in dollars per share)				1.89
Forfeited (in dollars per share)				2.10
Outstanding balance at the end of the period (in dollars per share)		$ 4.31		4.31		$ 4.48
Exercisable at the end of the period (in dollars per share)		5.20		5.20
Options vested and expected to vest at end of the period (in dollars per share)		$ 4.31		$ 4.31
Weighted Average Remaining Life in Years
Outstanding balance				7 years 2 months 12 days		7 years 6 months 29 days
Options exercisable at end of period				6 years 7 months 13 days
Options vested and expected to vest at end of the period				7 years 2 months 12 days
Aggregate Intrinsic Value
Outstanding balance		$ 2		$ 2
Options exercisable at the end of the period		1		1
Options vested and expected to vest at end of the period		$ 2		$ 2
Assumptions used to determine grant-date fair value
Expected Volatility				82.70%	66.94%
Weighted average risk-free interest rate				1.82%	0.80%
Expected dividend yield				0.00%	0.00%
Expected term (in years)				6 years 5 months 8 days	6 years 10 months 9 days
Expiration period				10 years
Options unvested at end of period (in dollars per share)		$ 1.35	$ 2.21	$ 1.35	$ 2.21
Compensation cost related to the non-vested awards not yet recognized		$ 3,151		$ 3,151
Weighted average period for recognition of compensation cost				1 year 7 months 28 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Outstanding at end(in dollars per share)		$ 1.35	$ 2.21	$ 1.35	$ 2.21
Minimum
Assumptions used to determine grant-date fair value
Vesting period				3 years
Maximum
Assumptions used to determine grant-date fair value
Vesting period				4 years
2016 Plan
Assumptions used to determine grant-date fair value
Annual increase in authorized shares (as a percent)	4.00%
Number of options or stock awards available for grant under the Plan		7,768,193		7,768,193
2022 Plan
Assumptions used to determine grant-date fair value
Number of options or stock awards available for grant under the Plan							7,500,000
Options to purchase common stock
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Stock-based compensation expense		$ 1,266	$ 912	$ 2,470	$ 1,745
Options to purchase common stock | Research and development
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Stock-based compensation expense		617	398	1,171	743
Options to purchase common stock | General and administrative
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Stock-based compensation expense		649	$ 514	1,299	$ 1,002
Restricted stock units to purchase common stock
Assumptions used to determine grant-date fair value
Aggregate grant fair value				6,640
Share-based payment arrangement, non vested award, excluding option, cost not yet recognized, amount		$ 4,902		$ 4,902
Weighted average period for recognition of compensation cost				2 years 5 months 4 days
Restricted stock units to purchase common stock | Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Awarded				2,575,000	275,000
Restricted stock units to purchase common stock | 2016 Plan
Assumptions used to determine grant-date fair value
Options unvested at end of period (in dollars per share)		$ 1.89		$ 1.89		$ 1.76
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Outstanding at the beginning				935,606
Awarded				2,575,000
Outstanding at the end		3,510,606		3,510,606		935,606
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Outstanding at beginning( in dollars per share)				$ 1.76
Awarded (in dollars per share)				1.94
Outstanding at end(in dollars per share)		$ 1.89		$ 1.89		$ 1.76